Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial compares the effect of belumosudil to a placebo in treating patients with
chronic graft versus host disease. Chronic graft versus host disease remains a major
complication of stem cell transplantation and can involve multiple organ systems. Belumosudil
is a ROCK2 selective inhibitor that works to reduce the immune system response causing the
chronic graft versus host disease. Giving belumosudil may better treat patients with chronic
graft versus host disease and prevent the need for starting additional immune suppressive
medications.